Probing the role of stearoyl-CoA desaturase–1 in hepatic insulin resistance
J. Clin. Invest. Matthew T. Flowers, et al. 116:1478 doi:10.1172/JCI28774 [Go to this article.]

Figure 1
Metabolic effects elicited by inhibition of SCD1 by ASOs. The inhibition of SCD1 in rodents with ASOs has been shown to prevent many high-fat diet–induced metabolic complications. i.p. delivery of SCD1 ASO results in decreased SCD1 expression in liver and adipose in both short-term (A) and long-term treatment periods (B). In studies by Gutiérrez-Juárez et al., short-term treatment (5 days) with i.p. SCD1 ASO prevented diet-induced insulin resistance (10) (A). In these studies, short-term liver-specific intraportal SCD1 ASO treatment also elicited these effects (A). Long-term treatment (4–10 weeks) with i.p. SCD1 ASO prevents diet-induced obesity and hepatic steatosis (9) (B). Adipose-specific inhibition as well as long-term liver-specific inhibition of SCD1 remain to be explored (A and B).